EGFR and neoplasm: The mechanisms underlying EGFR-TKI resistance are intricate and multifaceted, encompassing factors such as EGFR mutations, activation of signaling pathways, alterations in the tumor microenvironment, tumor heterogeneity, and histological transformation (Figure 1).